Atlanta, GA -Southeast BIO announced that it has selected ten semifinalists in its fifth annual BIO/Plan Competition. Established to promote the creation of new life science companies and the development of exceptional corporate partnering opportunities in the Southeast U.S., the BIO/Plan Competition targets technology transfer offices and entrepreneurs throughout the region to bring forward opportunities from leading Southeastern research universities and centers.
(more…)
DURHAM, N.C.–(BUSINESS WIRE)–Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders (“Synageva”), and Trimeris, Inc. (NASDAQ: TRMS) (“Trimeris”) announced today that Trimeris has filed a Form S-4 Registration Statement with the U.S. Securities and Exchange Commission (“SEC”) pertaining to the previously announced merger of Trimeris and Synageva. The Registration Statement has not yet been declared effective, and the information contained therein is subject to change. Once the Registration Statement has been declared effective, Synageva and Trimeris intend to set a date for a special meeting of each of their respective stockholders to approve the merger and deliver the final joint proxy statement/prospectus to their respective stockholders.
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsLang=en&newsId=20110718005536&div=928298533
ATLANTA, GA - TearScience Inc., a Morrisville, NC-based medical device company, announced Monday it has received FDA approval to market and sell its treatment for evaporative dry eye.
The LipiFlow treatment, which removes meibomian gland obstructions — a dysfunction linked to all forms of dry eye — is available immediately on a limited basis.
“We are gratified and blessed to have secured FDA clearance for the LipiFlow,” said Tim Willis, chief executive officer and co-founder of TearScience, in a written statement. “This marks an important day for ophthalmologists as now our advanced technology is available for their dry eye patients.”
TearScience’s LipiFlow is an outpatient procedure that takes about 30 minutes to administer in a doctor’s office.
TearScience, which employs about 30 people, has raised about $60 million in venture capital since being founded in 2005. It was rolling out its dry eye treatment in Canada and Europe earlier this year.
http://www.bizjournals.com/triangle/news/2011/07/11/tearscience-wins-fda-approval-for-dry.html
ATLANTA, GA - Mustard Tree Instruments, which makes drug testing equipment, has secured $4.8 million in first-round funding, the company announced Thursday.
(more…)
